Joshua Thaler, MD
Endocrinology, Diabetes & Metabolism · Seattle, WANPI 1780794743
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.4%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Eli Lilly accounts for 98.4% of it on its own, with 1 other manufacturer making up the rest.
Across 22 payments — averaging $169.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4K
- Rhythm Pharmaceuticals, Inc.$60
Across 3 payments — averaging $116,667 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$350K
What the payments were for
- Consulting fees$1,80048%
- Travel & lodging$1,42938%
- Food & beverage$43012%
- Education$602%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 21 | $3,659 |
| Rhythm Pharmaceuticals, Inc. | 1 | $60 |
How this compares
$3,718 in reported general payments places this provider in the 70th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 55 | $52,740 |
| JardianceEmpagliflozin | 44 | $40,585 |
| GenotropinSomatropin | 23 | $34,764 |
| MounjaroTirzepatide | 32 | $32,934 |
| OmnitropeSomatropin | 12 | $30,011 |
| TrulicityDulaglutide | 23 | $29,580 |
| JanuviaSitagliptin Phosphate | 11 | $11,820 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $5,682 |
| Testosterone Cypionate | 26 | $350 |
| Topiramate | 30 | $223 |
| Levothyroxine Sodium | 16 | $158 |
| Methimazole | 19 | $127 |
| Pioglitazone Hcl | 13 | $71 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Seattle
- Irl HirschSeattle$192K
- Nicole EhrhardtSeattle$111K
- Kristina UtzschneiderSeattle$72K
- Savitha SubramanianSeattle$71K
- William HagopianSeattle$30K
- Mahnaz MellatiSeattle$28K
- Alan ChaitSeattle$21K
- Jose GarciaSeattle$12K
- Carla GreenbaumSeattle$7K
- Tracy TyleeSeattle$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.